Moonlake immunotherapeutics MLTX.US Overview
MLTX AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
MLTX Current Performance
-2.51%
Moonlake immunotherapeutics
-1.83%
Avg of Sector
-0.40%
S&P500
MLTX Key Information
MLTX Revenue by Segments
Browsing restrictions can be lifted for a fee.
MLTX Net Income
Browsing restrictions can be lifted for a fee.
MLTX Cash Flow
Browsing restrictions can be lifted for a fee.
MLTX Profit Margin
Browsing restrictions can be lifted for a fee.
MLTX PE Ratio River
Browsing restrictions can be lifted for a fee.
MLTX Financial Forecast
Browsing restrictions can be lifted for a fee.
MLTX Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
MLTX Profile
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Price of MLTX
MLTX FAQ
When is MLTX's latest earnings report released?
The most recent financial report for Moonlake immunotherapeutics (MLTX) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MLTX's short-term business performance and financial health. For the latest updates on MLTX's earnings releases, visit this page regularly.
How much debt does MLTX have?
As of the end of the reporting period, Moonlake immunotherapeutics (MLTX) had total debt of 75.6M, with a debt ratio of 0.15. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does MLTX have?
At the end of the period, Moonlake immunotherapeutics (MLTX) held Total Cash and Cash Equivalents of 271.57M, accounting for 0.53 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is MLTX's EPS continuing to grow?
According to the past four quarterly reports, Moonlake immunotherapeutics (MLTX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.63. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of MLTX?
Moonlake immunotherapeutics (MLTX)'s Free Cash Flow (FCF) for the period is -38.18M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 151.81% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of MLTX?
The latest valuation data shows Moonlake immunotherapeutics (MLTX) has a Price-To-Earnings (PE) ratio of -17.45 and a Price/Earnings-To-Growth (PEG) ratio of 1.23. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.